BioCentury

7:00 AM GMT, Oct 24, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Kinase by kinase in PAH

In the span of three weeks, cancer drugs Gleevec imatinib and Sprycel dasatinib have shown divergent signals in pulmonary arterial hypertension. Gleevec met the primary endpoint of treating PAH symptoms in a Phase III trial, while FDA updated Sprycel's label to include warnings of increased PAH risk. The likely reason the two tyrosine kinase inhibitors showed polar opposite activity is that Sprycel

Read the full 621 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.